DELRAY BEACH, Fla.--(BUSINESS WIRE)--VeriTeQ Corporation (“VeriTeQ” or “Company”) (OTC Markets:VTEQ), a provider of implantable medical device identification and radiation dose measurement technologies, announced today that Zacks Investment Research (“Zacks”) has initiated coverage of the Company with an outperform rating.
Copies of the report may be obtained through Zacks Small Cap website at http://scr.zacks.com or at http://scr.zacks.com/files/doc_coverage/Med-Tech%20-%20Brian%20Marckx/VTEQ/February%2012%202014_VTEQ_Marckx.pdf.
Any opinions, judgments, estimates, or forecasts regarding the Company's historical or predicted performance or operations made by Zacks are its alone and do not represent opinions, judgments, estimates, or forecasts of the Company or its management. The Company does not by its reference to the research prepared by Zacks imply its endorsement or adoption of or concurrence with such information, conclusions, or recommendations.
VeriTeQ is focused on the unique device identification (“UDI”) of implantable and reusable medical devices through its Q Inside Safety Technology, and radiation dose measurement during radiation therapy. VeriTeQ’s FDA cleared Q Inside Safety Technology acts as an electronic serial number in breast implants and other implantable and reusable medical devices that gives physicians and patients access to secure online databases to retrieve device-specific data such as serial number, manufacturer name, date of manufacture, lot number, volume, size, and other data from the medical device manufacturer. Q Inside Safety Technology also provides an extra level of protection to the patient in the event of a recall or other safety event.
VeriTeQ’s radiation dosimeter, or biodosimetry, technologies include the DVS SmartMarker® and OneDose®. DVS SmartMarker is the world’s first FDA cleared, implantable, wireless radiation sensor, and is used to measure the radiation dose delivered to a patient directly from the site of the tumor during cancer treatment. DVS SmartMarker is cleared for use in breast and prostate cancer patients. Its OneDose® adhesive technology is FDA cleared for use in cancer patients being treated with external beam radiation to measure radiation dose levels at the skin surface.
VeriTeQ’s intellectual property portfolio includes more than 100 patents issued, patents pending, and patent licenses. VeriTeQ also has data analytics capabilities related to information gathered by its technologies.
For more information on VeriTeQ, please visit www.veriteqcorp.com.
Statements in this press release about our future constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and our actual results could differ materially from expected results. These risks and uncertainties include, without limitation, VeriTeQ’s ability to commercially launch its Q Inside Safety Technology; the Company’s ability to target the UDI sector and medical device manufacturers; the Company’s ability to commercialize its radiation dosimetry technologies; VeriTeQ’s ability to raise capital; as well as other risks. Additional information about these and other factors may be described in VeriTeQ’s Forms 10-Q, filed on August 9, 2013 and November 14, 2013, and future filings with the Securities and Exchange Commission The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.